June 11, 2018 Source: FiercePharma 232
Emergent BioSolutions, Gaithersburg, Maryland-based Biopharmaceutical Company announced that it will invest $50 million for the next three years to expand the manufacturing capacity for its Camden fill-finish in Baltimore facility. By the time the project has been completed in three years, it is expected to add up 60 jobs.
Sean Kirk, senior, VP of manufacturing operations and head of its CDMO business, said in a statement “The extension of our Camden facility is a tremendous capital investment that will initiate quantifiable benefits for our customers. This investment in innovation and technology not only expands our client-centric benefactions to maintain future growth but also boost our history of quality and to ensure the maximum focus on patient safety in pursuit of our mission, to protect and improve lives.”
The expansion comes after October 2017 when Emergent acquired ACAM2000 (only smallpox vaccine approved by the U.S. FDA) plant in Massachusetts, Canton, from Sanofi. In November the plant was approved by the FDA to manufacture ACAM2000. Approval came far ahead of expectations. It was stated earlier by CEO Daniel Abdun-Nabi that the license was expected to come in 2018.
Emergent acquired ACAM200 and the plant for $125 million from Sanofi, under a CDC deal.By Ddu
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.